<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td><hr align="center" size="1" noshade width="15%"></td> </tr>
</table>
<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  December 8, 2005</font></p>
<p align="center"><font size="2" face="serif"><u>Savient Pharmaceuticals, Inc.</u></font><br>
<font size="2" face="serif">(Exact name of registrant as specified in charter)</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr align="center" valign="bottom" bgcolor="#ffffff">
<td width="33%"><font size="2" face="serif"><u>Delaware</u></font></td>
<td width="34%"><font size="2" face="serif"><u>0-15313</u></font></td>
<td width="33%"><font size="2" face="serif"><u>13-3033811</u></font></td>
</tr>
<tr align="center" valign="bottom" bgcolor="#FFFFFF">
<td width="33%"><font size="2" face="serif">(State or other juris-<br>
  diction of incorporation</font></td>
<td width="34%"><font size="2" face="serif">(Commission<br>
  File Number)</font></td>
<td width="33%"><font size="2" face="serif">(IRS Employer<br>
  Identification No.)</font></td>
</tr>
</table>
<br><br>
<p align="center"><font size="2" face="serif">One Tower Center, 14th Floor</font><br>
<font size="2" face="serif"><u>East Brunswick, New Jersey 08816</u></font><br>
<font size="2" face="serif">(Address of principal executive offices) (Zip Code)</font></p>
<p align="center"><font size="2" face="serif">Registrant&#146;s telephone number, including area code:  (732) 418-9300</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif"><u>Not applicable</u></font></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Former name or former address, if changed since last report)</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif"><img src="emptybox.gif"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="left"><font size="2" face="serif"><b>Item 1.01.  Entry into a Material Definitive Agreement</b></font></p>
<p align="left"><font size="2" face="serif"><b><i>Master Agreement</i></b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 8, 2005, Savient Pharmaceuticals, Inc. (&#147;<u>Savient</u>&#148;) entered into a Master Agreement (the &#147;<u>Master Agreement</u>&#148;) with Ferring International Centre SA (&#147;<u>Ferring International</u>&#148;), Ferring B.V. (&#147;<u>Ferring BV</u>&#148;) and Ferring Pharmaceuticals Inc. (&#147;<u>Ferring USA</u>&#148;).  The Master Agreement amends the Share Purchase Agreement with Ferring BV and the Asset Purchase Agreement with Ferring International, each entered into on March 23, 2005, which together provided for the sale to Ferring BV and Ferring International of Savient&#146;s global biologics business.&nbsp; The Master Agreement also amends the Copromotion Agreement (the
&#147;<u>Copromotion Agreement</u>&#148;) between Savient and Ferring Pharmaceuticals Inc., also entered into on March 23, 2005, which provided for the copromotion by Savient and Ferring of Euflexxa<sup>TM</sup>.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Master Agreement provides for Savient&#146;s exit of the Copromotion Agreement.  Pursuant to the Master Agreement, in lieu of Savient&#146;s $20 million obligation under the Copromotion Agreement, on December 15, 2005, Savient will pay to Ferring $15.6 million, representing a $17.8 million termination payment less accrued expenses to date under the Copromotion Agreement of approximately $2.2 million.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Master Agreement also provides for the modification and acceleration of the $25 million of total post-closing payments required by Ferring in connection with its acquisition of Savient&#146;s global biologics manufacturing business.  In lieu of these post-closing payments, Ferring will pay $15.7 million to Savient on December 15, 2005, and will pay $6.7 million to Savient on or before March 31, 2006.  Finally, the Master Agreement confirms the resolution by Ferring and Savient of the post-closing working capital calculation relating to Ferring&#146;s acquisition of the global biologics manufacturing business, resulting in a $755,000 payment by Ferring to Savient, also to be paid on December 15, 2005.</font></p>
<p align="left"><font size="2" face="serif"><b><i>Incorporation By Reference</i></b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing description of the Master Agreement is not complete and is qualified in its entirety by reference to the full text of the actual agreement, which is filed as an exhibit to this Form 8-K.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01.  Financial Statements and Exhibits</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Exhibit Index attached hereto.</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>  <table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top"> <td align="left"><font size="1" face="serif">&nbsp;</font></td>
<td colspan="2" align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td> </tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td colspan="2" align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">Date:  December 14, 2005</font></td>
<td colspan="2" align="left"><font size="2" face="serif">By:   <u>/s/ Philip K. Yachmetz</u></font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Philip K. Yachmetz<br>Senior Vice President &#150; Corporate<br>Strategy &amp; General Counsel</font></td>
</tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif">EXHIBIT INDEX</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"><u>Exhibit No.</u></font></td>
<td align="left" width="2%">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="59%" align="left"><font size="2" face="serif"><u>Description</u></font></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top">
<td></td>
<td></td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">2.1</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Share Purchase Agreement dated March 23, 2005, between Savient Pharmaceuticals, Inc. and Ferring B.V. **</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">2.2</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Asset Purchase Agreement dated March 23, 2005, between Savient Pharmaceuticals, Inc. and Ferring International Centre SA **</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">2.3</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Master Agreement dated December 8, 2005, between Savient Pharmaceuticals, Inc.,
Ferring International Centre SA, Ferring B.V. and Ferring Pharmaceuticals Inc. *</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">10.1</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Copromotion Agreement dated March 23, 2005, between Savient Pharmaceuticals, Inc. and Ferring Pharmaceuticals Inc.**</font></td>
<td align="left">&nbsp;</td>
</tr>
</table>
<p align="left"><font size="2" face="serif">* The exhibits and schedules to this agreement have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K.  Savient will furnish copies of any of the exhibits and schedules to the U.S. Securities and Exchange Commission upon request.</font></p>
<p align="left"><font size="2" face="serif">** These agreements have been previously filed as exhibits to Form 8-K dated March 23, 2005.</font></p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b410248_8k.htm", "description": "8-K", "secsgml_size_bytes": 12069}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "051264723"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):  December 8, 2005
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Delaware
0-15313
13-3033811
(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.  Entry into a Material Definitive Agreement
Master Agreement
On December 8, 2005, Savient Pharmaceuticals, Inc. ("
Savient
") entered into a Master Agreement (the "
Master Agreement
") with Ferring International Centre SA ("
Ferring International
"), Ferring B.V. ("
Ferring BV
") and Ferring Pharmaceuticals Inc. ("
Ferring USA
").  The Master Agreement amends the Share Purchase Agreement with Ferring BV and the Asset Purchase Agreement with Ferring International, each entered into on March 23, 2005, which together provided for the sale to Ferring BV and Ferring International of Savient's global biologics business.  The Master Agreement also amends the Copromotion Agreement (the
"
Copromotion Agreement
") between Savient and Ferring Pharmaceuticals Inc., also entered into on March 23, 2005, which provided for the copromotion by Savient and Ferring of Euflexxa
TM
.
The Master Agreement provides for Savient's exit of the Copromotion Agreement.  Pursuant to the Master Agreement, in lieu of Savient's $20 million obligation under the Copromotion Agreement, on December 15, 2005, Savient will pay to Ferring $15.6 million, representing a $17.8 million termination payment less accrued expenses to date under the Copromotion Agreement of approximately $2.2 million.
The Master Agreement also provides for the modification and acceleration of the $25 million of total post-closing payments required by Ferring in connection with its acquisition of Savient's global biologics manufacturing business.  In lieu of these post-closing payments, Ferring will pay $15.7 million to Savient on December 15, 2005, and will pay $6.7 million to Savient on or before March 31, 2006.  Finally, the Master Agreement confirms the resolution by Ferring and Savient of the post-closing working capital calculation relating to Ferring's acquisition of the global biologics manufacturing business, resulting in a $755,000 payment by Ferring to Savient, also to be paid on December 15, 2005.
Incorporation By Reference
The foregoing description of the Master Agreement is not complete and is qualified in its entirety by reference to the full text of the actual agreement, which is filed as an exhibit to this Form 8-K.
Item 9.01.  Financial Statements and Exhibits
(c)      Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC.
Date:  December 14, 2005
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Senior Vice President – Corporate
Strategy & General Counsel
EXHIBIT INDEX
Exhibit No.
Description
2.1
Share Purchase Agreement dated March 23, 2005, between Savient Pharmaceuticals, Inc. and Ferring B.V. **
2.2
Asset Purchase Agreement dated March 23, 2005, between Savient Pharmaceuticals, Inc. and Ferring International Centre SA **
2.3
Master Agreement dated December 8, 2005, between Savient Pharmaceuticals, Inc.,
Ferring International Centre SA, Ferring B.V. and Ferring Pharmaceuticals Inc. *
10.1
Copromotion Agreement dated March 23, 2005, between Savient Pharmaceuticals, Inc. and Ferring Pharmaceuticals Inc.**
* The exhibits and schedules to this agreement have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K.  Savient will furnish copies of any of the exhibits and schedules to the U.S. Securities and Exchange Commission upon request.
** These agreements have been previously filed as exhibits to Form 8-K dated March 23, 2005.